Pharmacologic Treatment of Obesity: Symposium Overview
نویسندگان
چکیده
منابع مشابه
Pharmacologic Treatment of Obesity
This review offers an overview of physiological agents, current therapeutics, as well as medications, which have been extensively used and those agents not currently available or non-classically considered anti-obesity drugs. As obesity - particularly that of central distribution - represents an important triggering factor for insulin resistance, its pharmacological treatment is relevant in the...
متن کاملPharmacologic treatment of pediatric obesity.
Question There is a large population of overweight and obese children in my clinic. What medications for treatment of obesity are effective and can be used in children? Answer Orlistat is the only medication indicated by the US Food and Drug Administration for the treatment of obesity in adolescents. It is approved by the Food and Drug Administration for use in adolescents aged 12 years and old...
متن کاملPresent and Future: Pharmacologic Treatment of Obesity
Obesity now presents one of the biggest health problems of our times. Diet and exercise are best for both prevention and treatment; unfortunately, both require much discipline and are difficult to maintain. Medications offer a possible adjunct, but their effect is modest, they are limited by side effects, and the weight loss lasts only as long as the drug is being taken, since as soon as treatm...
متن کاملMeta-analysis: pharmacologic treatment of obesity.
BACKGROUND In response to the increase in obesity, pharmacologic treatments for weight loss have become more numerous and more commonly used. PURPOSE To assess the efficacy and safety of weight loss medications approved by the U.S. Food and Drug Administration and other medications that have been used for weight loss. DATA SOURCES Electronic databases, experts in the field, and unpublished ...
متن کاملSYMPOSIUM Pharmacologic interventions
S21 Am J Health-Syst Pharm—Vol 70 May 15, 2013 Suppl 1 of anticoagulant activity. Thromb Haemost. 2010; 103:1116-27. 48. Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health-Syst Pharm. 2008; 65:1520-9. 49. Kubitza D, Becka M, Mueck W et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, dir...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Obesity Research
سال: 1995
ISSN: 1071-7323
DOI: 10.1002/j.1550-8528.1995.tb00207.x